Condition

Gastroesophageal Junction Adenocarcinoma clinical trials and research

• 45Clinical trials
• 1New in 30 days
• 37Countries

Newest Gastroesophageal Junction Adenocarcinoma clinical trials

All recruiting trials (45)

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• AI-powered tumor response assessment after preoperative treatment in stomach and gastroesophageal junction cancer

  Researchers are testing whether an AI tool called DeepTRG can reliably measure how much cancer remains in tissue removed after preoperative therapy in stomach and GEJ cancer, without needing a human to correct the AI results.

  Recruiting Hebei Medical University · Shijiazhuang, None Selected · NCT07849608

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Chemoradiotherapy with CAPOX and SHR-1701 for unresectable gastric or GEJ cancer

  This study tests whether adding SHR-1701 to radiotherapy and CAPOX helps patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer see if they harm or help, with the goal of delaying progression and enabling possible surgery.

  Recruiting at 3 sites Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Shenzhen, Guangdong and 2 other locations · NCT07689851

• TAIC FOLFOX for unresectable gastric and gastroesophageal junction cancer

  This study tests a combination of TAIC and FOLFOX chemotherapy to see if it helps adults with unresectable gastric cancer or gastroesophageal junction adenocarcinoma live longer and feel better.

  Recruiting Phase 2 Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing · NCT07655024

• HIPEC-primed therapy with serplulimab plus SOX/XELOX for locally advanced gastric cancer

  This study tests a HIPEC-priming approach followed by PD-1 blocker–based chemotherapy to see if it helps people with locally advanced gastric cancer who have not yet spread.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07621484

• BL-M05D1 vs investigator's choice in CLDN 18.2-positive advanced gastric/GEJ cancer

  This phase 3 study tests BL-M05D1 against the treating physician’s chosen therapy in adults with CLDN 18.2-positive advanced gastric or GEJ cancer after first-line treatment.

  Recruiting Phase 3 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07518147

• IBI343 with sintilimab and SOX before and during surgery for resectable locally advanced gastric or GEJ cancer

  A phase II trial tests whether adding IBI343 to sintilimab plus a SOX chemotherapy regimen around surgery helps people with CLDN18.2-positive, locally advanced gastric or GEJ cancer who are candidates for curative D2 surgery.

  Recruiting Phase 2 Innovent Biologics (Suzhou) Co. Ltd. · Beijing, Beijing Municipality · NCT07483567

• Sonesitatug vedotin plus capecitabine, with or without rilvegostomig, for CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma

  This trial will test whether adding sonesitatug vedotin to capecitabine, with or without rilvegostomig, helps people with untreated CLDN18.2-positive, HER2-negative advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma.

  Recruiting at 158 sites Phase 3 AstraZeneca · Birmingham, Alabama and 313 other locations · NCT07431281

• Zolbetuximab with chemotherapy for HER2-negative, Claudin 18.2–positive metastatic gastric or gastroesophageal junction adenocarcinoma

  This project will try zolbetuximab together with FOLFOX or XELOX as first-line treatment for adults whose HER2-negative stomach or gastroesophageal junction cancers strongly express Claudin 18.2.

  Recruiting European Institute of Oncology · Milan · NCT07427992

• SHR-1701 plus rivoceranib (with or without SHR-2554) for advanced gastric and gastroesophageal junction adenocarcinoma after first-line immunotherapy

  This will see if combining SHR-1701 with rivoceranib, with or without SHR-2554, helps people with advanced gastric or gastroesophageal junction cancer whose disease progressed on or who couldn't tolerate first-line immunotherapy.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07311408

• Short-course radiotherapy plus immunochemotherapy before surgery for gastroesophageal junction cancer

  This will test whether giving short-course (hypofractionated) radiotherapy together with a PD-1 drug (serplulimab) and TS-1 chemotherapy before surgery helps people with locally advanced, resectable gastroesophageal junction adenocarcinoma.

  Recruiting at 4 sites Phase 1/2 West China Hospital · Xiamen, Fujian and 3 other locations · NCT07182565

• CT041 after first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction cancer

  This study will test CT041, an autologous CLDN18.2-targeted CAR T-cell treatment, for people with advanced gastric or gastroesophageal junction adenocarcinoma after completing first-line therapy.

  Recruiting Beijing GoBroad Hospital · Beijing · NCT07179484

• BL-M07D1 versus chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer

  This trial tests whether BL-M07D1 works better than a doctor's choice of chemotherapy for adults with HER2‑positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after first‑line anti‑HER2 therapy has failed.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Harbin, Heilongjiang and 1 other locations · NCT07152405

• SHR2554 combined with other cancer medicines for advanced stomach or gastroesophageal junction adenocarcinoma

  This study will test if adding SHR2554 to other anti-cancer treatments helps people with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

  Recruiting at 2 sites Phase 2 Jiangsu HengRui Medicine Co., Ltd. · Harbin, Heilongjiang and 1 other locations · NCT07102901

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

• Short-course higher-dose radiotherapy plus immunochemotherapy to make gastroesophageal junction cancer removable

  This test adds short-course, higher-dose radiotherapy to PD-1 immunotherapy (sintilimab) and SOX chemotherapy for adults with locally advanced or initially unresectable gastroesophageal junction adenocarcinoma to see if tumors shrink enough for surgery.

  Recruiting at 4 sites Phase 1/2 West China Hospital · Xiamen, Fujian and 3 other locations · NCT07072351

• Subcutaneous versus intravenous tislelizumab with chemotherapy for unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

  This will test whether giving tislelizumab as a subcutaneous injection instead of an IV infusion, both with chemotherapy, works well and is safe as first treatment for adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

  Recruiting at 88 sites Phase 3 BeOne Medicines · Chandler, Arizona and 94 other locations · NCT07043400

• Adding paclitaxel into the abdominal cavity for gastric cancer that has spread to the peritoneum

  This trial will try adding paclitaxel delivered directly into the abdomen to standard IV chemotherapy for people with gastric or gastroesophageal junction cancer that has spread to the lining of the abdominal cavity to see if it slows disease growth and helps them live longer.

  Recruiting at 78 sites Phase 2/3 Eastern Cooperative Oncology Group · Irvine, California and 77 other locations · NCT07001748

• Treatment for advanced gastric cancer using BC001, Sintilimab, and XELOX

  This study is testing a new treatment combining BC001, Sintilimab, and XELOX to see if it helps people with advanced gastric cancer feel better and live longer.

  Recruiting Phase 1 Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06773312

• New treatment for HER2-positive gastric cancer using rilvegostomig and chemotherapy

  This study is testing a new treatment combining rilvegostomig with chemotherapy for people with HER2-positive gastric cancer to see if it works better than current standard treatments.

  Recruiting at 253 sites Phase 3 AstraZeneca · Anchorage, Alaska and 303 other locations · NCT06764875

• Combination treatment for advanced gastric cancer with HER2 overexpression

  This study is testing a new combination treatment for patients with advanced gastric cancer that has high levels of HER2 to see if it can improve their outcomes.

  Recruiting at 2 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT06560528

• Combination of OBP-301 and Pembrolizumab for Advanced Esophagogastric Cancer

  This study is trying a new treatment combining OBP-301 and pembrolizumab to see if it can help people with advanced esophageal and gastric cancer who haven't responded well to previous immunotherapy.

  Recruiting at 2 sites Phase 2 Weill Medical College of Cornell University · New York, New York and 1 other locations · NCT06340711

• Finding the right dose of zongertinib for HER2+ cancer treatment

  This study is testing the best dose of zongertinib to see if it can help adults with hard-to-treat HER2+ cancers shrink their tumors.

  Recruiting at 98 sites Phase 1/2 Boehringer Ingelheim · Cerritos, California and 103 other locations · NCT06324357

• Comparing home and clinic administration of nivolumab for cancer treatment

  This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT06265285

• Combining Disitamab Vedotin and Cadonilimab for HER2-expressing Gastric Cancer

  This study is testing if combining two treatments, Disitamab Vedotin and Cadonilimab, can help people with advanced gastric cancer that has not responded to earlier treatments.

  Recruiting at 5 sites Phase 2/3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 11 other locations · NCT06221748

• Combination treatment for advanced gastric and gastroesophageal junction cancer

  This study is testing a new combination of two medications with chemotherapy to see if it can help adults with advanced stomach or gastroesophageal junction cancer.

  Recruiting Phase 2 Harbin Medical University · Harbin · NCT06196697

• Combination therapy for advanced gastric cancer

  This study is testing a new combination treatment for advanced gastric cancer to see if it works better than the usual options for patients with a specific type of the disease.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 10 other locations · NCT06155383

• Testing a new drug for adults with advanced solid tumors

  This study is testing a new drug for adults with advanced solid tumors that haven't responded to other treatments to see if it can help them.

  Recruiting at 43 sites Phase 1 Seagen Inc. · Phoenix, Arizona and 47 other locations · NCT06131840

• Combining radiotherapy and immunotherapy for limited metastatic gastric cancer

  This study is testing a new treatment that combines radiation, chemotherapy, and immunotherapy to see if it can help people with limited metastatic gastric cancer live longer and improve their health.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06121700

• Testing NEO212 for treating certain brain tumors and metastases

  This study is testing a new treatment called NEO212 for people with certain types of brain tumors to see if it is safe and effective when combined with standard treatments.

  Recruiting at 8 sites Phase 1/2 Neonc Technologies, Inc. · Beverly Hills, California and 7 other locations · NCT06047379

• Combining TRK-950 with Ramucirumab and Paclitaxel for Gastric Cancer

  This study is testing if adding a new drug called TRK-950 to the standard treatments ramucirumab and paclitaxel can help people with gastric cancer live longer and feel better.

  Recruiting at 27 sites Phase 2 Toray Industries, Inc · Duarte, California and 26 other locations · NCT06038578

• Total neoadjuvant chemotherapy for advanced gastric and gastroesophageal cancer

  This study is testing two different chemotherapy plans for people with advanced stomach cancer to see which one helps them better tolerate treatment and successfully have surgery.

  Recruiting at 2 sites Phase 2/3 Ukrainian Society of Clinical Oncology · Vilnius and 1 other locations · NCT06028737

• Robotic surgery and heated chemotherapy for gastric cancer with peritoneal spread

  This study is testing if a new robotic surgery combined with heated chemotherapy can help people with advanced stomach cancer that has spread to the abdominal lining feel better and live longer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT05753306

• Collecting blood samples to evaluate tests for early cancer detection

  This study is collecting blood and tissue samples from people with and without cancer to see if new tests can help detect cancer earlier.

  Recruiting at 619 sites Alliance for Clinical Trials in Oncology · Anchorage, Alaska and 750 other locations · NCT05334069

• Evaluating the impact of tumor microenvironment on treatment outcomes in advanced gastric cancer

  This study is trying to see how the environment around tumors in patients with advanced stomach cancer affects how well their treatment works.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT04850729

• Combination treatment for gastroesophageal junction and esophagogastric cancer

  This study is testing a new combination of liposomal irinotecan with standard treatments to see if it helps people with gastroesophageal junction or esophagogastric cancer feel better.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT04656041

• Using NBTXR3 with chemotherapy and radiation to treat esophageal cancer

  This study is testing a new drug called NBTXR3, combined with chemotherapy and radiation, to see if it can safely help people with esophageal cancer who haven't been treated before.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT04615013

• Collection of tumor samples from cancer patients for diagnostic test development

  This study is collecting tumor samples from cancer patients who are getting certain treatments to help create better tests for managing cancer in the future.

  Recruiting Cofactor Genomics, Inc. · San Francisco, California · NCT04510129

• Combining chemotherapy with HIPEC for gastric cancer treatment

  This study tests if adding a special heated chemotherapy treatment during surgery can help people with certain types of stomach cancer do better than just using chemotherapy alone.

  Recruiting at 15 sites Phase 3 Krankenhaus Nordwest · Aachen and 14 other locations · NCT04447352

• Testing a new drug for advanced solid tumors

  This study is testing a new drug called sigvotatug vedotin to see if it can safely help people with advanced solid tumors, both on its own and with other treatments.

  Recruiting at 145 sites Phase 1 Seagen Inc. · Anchorage, Alaska and 157 other locations · NCT04389632

• Combining irinotecan with multiple chemotherapy agents for cancer treatment

  This study is testing a new combination of chemotherapy drugs, including irinotecan, to see if it can safely help people with advanced gastrointestinal cancers like pancreatic and gastroesophageal junction adenocarcinoma who haven't had success with other treatments.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois · NCT04361708

• Registry for gastric and esophageal cancer treatments in Germany

  This study is collecting information on how patients in Germany with advanced esophageal and stomach cancers are treated to see how well different treatments work in real life.

  Recruiting iOMEDICO AG · Multiple Locations · NCT04290806

• Treatment of advanced solid tumors with APL-101 for specific genetic mutations

  This study is testing a new oral medication called APL-101 to see if it helps people with advanced lung cancer and other solid tumors that have certain genetic changes, especially those who haven't had success with standard treatments.

  Recruiting at 32 sites Phase 2 Apollomics Inc. · Los Angeles, California and 34 other locations · NCT03175224

Related topics

Quick answers

How many Gastroesophageal Junction Adenocarcinoma clinical trials are recruiting right now?

45, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 37 countries. The most sites are in China (25 trials), United States (22 trials), Spain (8 trials), United Kingdom (8 trials), France (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 16, Phase 1: 8, Phase 3: 6, Phase 1/2: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →